The primary objective was to determine the effect of statin-fibrate combination therapy on inflammatory biomarkers in patients with diabetes. BACKGROUND Atherosclerosis is a long-term, chronic inflammatory disease that is exacerbated in patients with diabetes.
Diabetes mellitus confers a 2-to 4-fold increase in cardiovascular risk compared with the general population (1) . Although microvascular complications of diabetes result in increased rates of morbidity, macrovascular complications, including coronary artery disease, often cause death (2) . Cardiovascular disease and diabetes are both associated with elevated levels of inflammatory biomarkers, including C-reactive protein (CRP) (3) . C-reactive protein is the most well-studied inflammatory marker of atherothrombotic risk (4) and is incremental to the Framingham Risk Score (5). Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) is a newer inflammatory biomarker that has been proposed to be more specific to vascular inflammation.
Statin and fibrate therapy have been shown to variably lower levels of CRP (6, 7) , as well as levels of Lp-PLA 2 (8) . However, the influence of a statin and fibrate combination on levels of inflammatory markers requires further investigation (9, 10) . Therefore, among patients with type II diabetes, we assessed the effect of statin, fibrate, and combination therapy on inflammatory biomarkers in the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study.
METHODS

Patients.
Patients with a clinical diagnosis of type II diabetes mellitus and biochemical evidence of mixed dyslipidemia were considered for enrollment in the study. The study protocol was approved by the institutional review board, and all patients provided written informed consent. Patients meeting prescreening criteria were required to undergo wash-out if currently receiving lipid therapy. A complete list of inclusion/exclusion criteria is found in Table 1 . Protocol. We undertook a single-center, randomized, double-blind, and placebo-controlled 12-week study. Those participants satisfying all inclusion/exclusion criteria were assigned randomly to receive 1 of 3 daily oral treatments: simvastatin 20 mg taken in the evening/fenofibrate placebo taken in the morning with food, fenofibrate 160 mg taking in the morning with food/simvastatin placebo taken in the evening, or simvastatin 20 mg taken in the evening and fenofibrate 160 mg taken in the morning with food. Coordinators, investigators, statistical personnel, and patients remained blinded to patient treatment assignment.
Follow-up visits were scheduled 6 and 12 weeks after randomization, where assessment of adverse events and 12-h fasting laboratory measurements were made. A creatine kinase was drawn if the patient complained of any muscle aches at those visits or at any time throughout the study period. Laboratory measurements. Laboratory samples were analyzed in an Intermountain Healthcare laboratory (LDS Hospital, Salt Lake City, Utah, or McKay Dee Hospital, Ogden, Utah). Total cholesterol and triglycerides were quantified using dry-slide measurement on the VITROS 950 Analyzer (Ortho Clinical Diagnostics, Raritan, New Jersey). High-density lipoprotein cholesterol (HDL-C) was The concentration of high-sensitivity C-reactive protein (hsCRP) was determined using an immunoturbidimetric assay on the Hitachi 917 analyzer (Roche Diagnostics, Indianapolis, Indiana), using reagents and calibrators from Denka Seiken (Niigata, Japan). This assay has a sensitivity of 0.03 mg/l. The day-to-day variability of the assay at concentrations of 0.91 mg/l, 3.07 mg/l, and 13.38 mg/l are 2.81%, 1.61%, and 1.1%, respectively. Any patient with an hsCRP Ͼ10 mg/l was excluded from the analysis. We measured Lp-PLA 2 by using the PLAC test (diaDexus, Inc., San Francisco, California), and testing was performed at diaDexus, Inc., as described in the package insert, a modification of the originally published protocol (11) .
Statistical analysis. This study was designed to provide an 80% power to detect a 20% difference in achievement of the primary study end point (percent of patients achieving triglyceride levels of Ͻ200 mg/dl after 12 weeks of treatment, which results are not described here) among study treatments with 100 patients in each group. Analysis was performed blinded by assigning each patient a letter (A, B, or C) that corresponded to their treatment group using the intention-to-treat model. Descriptive statistics were used to summarize characteristics of the study population and biomarker measurements. For evaluations of concentrations of triglycerides, hsCRP, and Lp-PLA 2 , these variables were transformed using the natural logarithm to normalize the distributions before within-group analyses. Differences in baseline and 12-week levels were evaluated using the paired t test. The effect of study therapy on mean percent reduction from baseline levels of lipids, hsCRP, and Lp-PLA 2 was analyzed using analysis of variance and the Tukey's HSD The p values represent a comparison between baseline and 12-week levels within each treatment. *Median levels reported due non-normal distribution of the data. HDL-C ϭ high-density lipoprotein cholesterol; LDL-C ϭ low-density lipoprotein cholesterol. Table 2 summarizes the baseline characteristics of the overall study population (n ϭ 300) and also among each treatment group. Overall, significant changes between baseline and 12 weeks were found in median levels of hsCRP: 2.11 and 1.81 mg/l (Ϫ14.6%, p ϭ 0.004); of Lp-PLA 2 : 320.9 and 229.4 ng/ml (Ϫ33.2%, p Ͻ 0.0001); of triglycerides: 260.0 and 160.0 mg/dl (Ϫ36.2%, p Ͻ 0.0001); in mean levels of total cholesterol: 228.7 and 176.9 mg/dl (Ϫ21.6%, p Ͻ 0.0001); of LDL-C: 137.9 and 101.9 mg/dl (Ϫ23.2%, p Ͻ 0.0001); of HDL-C: 36.6 and 40.3 mg/dl (ϩ11.3%, p Ͻ 0.0001); and of non-HDL-C: 192.1 and 136.2 (Ϫ27.6%, p Ͻ 0.0001), respectively. Table 3 shows levels of hsCRP, Lp-PLA 2 , and lipids at baseline and 12 weeks with their percent change by treatment group. Table  4 displays comparisons of absolute changes among treatment groups for their ability to modify lipids, hsCRP, and Lp-PLA 2 . No significant difference in effect on either inflammatory marker was noted between treatment groups. For those missing 12-week information (n ϭ 10), analysis using 6-week information was performed and did not alter the results. For those with increased levels of baseline hsCRP (Ͼ2.0 mg/l, n ϭ 141), the median percent change within each treatment arm was greater and highly significant (Fig. 1) . For these patients, median hsCRP levels within each treatment at baseline and 12 weeks were fenofibrate ϭ 4.05 and 2.79 mg/l, simvastatin ϭ 3.88 and 2.83 mg/l, and combination ϭ 3.98 and 2.93 mg/l, respectively. Likewise, the percent reduction of Lp-PLA 2 was greatest among those with baseline levels greater than the median of 320.9 (n ϭ 137) (Fig. 2) . For patients with Lp-PLA 2 greater than the median, median levels at baseline and 12 weeks were fenofibrate ϭ 459.3 and 237.9 ng/ml, simvastatin ϭ 434.9 and 231.9 ng/ml, and combined ϭ 439.1 and 228.2 ng/ml, respectively.
RESULTS
The percent change of hsCRP was not correlated with the percent change of Lp-PLA 2 or any lipids. A decrease in Lp-PLA 2 was significantly correlated with a decrease in total cholesterol (r ϭ 0.46, p Ͻ 0.001), LDL-C (r ϭ 0.35, p Ͻ 0.001), and non-HDL-C (r ϭ 0.45, p Ͻ 0.001) with simvastatin but not with fenofibrate or combination therapy (Fig. 3) . No other treatments correlated significantly with inflammatory markers and lipids. Clinical adverse events were similar among all treatment groups. There were no cases of rhabdomyolysis, clinical myopathy (creatine kinase Ͼ10 upper limit of control), persistent myalgias, or adverse liver-related events, even among those subjects who dropped out of the study (n ϭ 19). No serious drug-related clinical adverse events were noted throughout the study.
DISCUSSION
In this double-blind, placebo-controlled randomized study of 300 dyslipidemic patients with type II diabetes, we observed highly significant modifications in plasma concentrations of Lp-PLA 2 , total cholesterol, LDL-C, HDL-C, triglycerides, and non-HDL-C in addition to a trend toward reduction of hsCRP by the combination therapy of simvastatin and fenofibrate. Combination therapy was not more effective in modifying levels of hsCRP and Lp-PLA 2 than either simvastatin or fenofibrate monotherapy; however, it was superior in reducing total cholesterol, LDL-C, and non-HDL-C concentrations compared with fenofibrate and in reducing triglyceride levels compared with simvastatin.
Four points contribute to the clinical relevance and importance of this study. 1) The magnitude of reduction by fenofibrate, simvastatin, and combination therapy was greatest when concentrations of hsCRP and Lp-PLA 2 were increased Ͼ2.0 mg/l and the median value of 320.9 ng/ml, respectively. 2) The ability of fenofibrate to lower hsCRP was comparable with simvastatin and combination therapy. 
